



A convenient synthesis of (*Z*)-1-chloro-1-alkenes and (*Z*)-1-chloro-2-alkoxy-1-alkenes

Rachid Baati,^a D. K. Barma,^b U. Murali Krishna,^b Charles Mioskowski^{a,*} and J. R. Falck^{b,*}


^aUniversité Louis Pasteur de Strasbourg, Faculté de Pharmacie, Laboratoire de Synthèse Bio-Organique (UMR 7514), 67401 Illkirch, France

^bDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390-9038, USA

Received 26 September 2001; revised 27 November 2001; accepted 28 November 2001

Abstract—Mild, room temperature CrCl₂ reduction of 1,1,1-trichloroalkanes stereoselectively generates (*Z*)-1-chloro-2-substituted-1-alkenes in excellent yields. © 2002 Elsevier Science Ltd. All rights reserved.

(*Z*)-1-Chloro-1-alkenes are useful synthetic intermediates¹ as well as structural components in some medicinally significant pharmaceuticals² and natural products.³ They are most often prepared by Wittig and related olefinations,⁴ selective hydrogenation,⁵ hydroboration/protonolysis⁶ of 1-chloro-1-alkynes, transition metal-catalyzed additions,⁷ or *E*₂-eliminations.⁸ However, extant methodology is sometimes unreliable, inefficient, and/or generates mixtures of geometric isomers. These limitations are particularly relevant for conjugated systems and for (*Z*)-1-chloro-2-alkoxy-1-alkenes (α -chloroenol ethers), whose sensitivity to a wide variety of reagents and acids makes their preparation quite challenging.⁹ In continuation of our investigations¹⁰ of organochromium methodology, we report herein a broadly applicable and convenient preparation of (*Z*)-1-chloro-1-alkenes and (*Z*)-1-chloro-2-alkoxy-1-alkenes via CrCl₂ reduction of 1,1,1-trichloroalkanes in THF at ambient temperature (Eq. (1)).¹¹



The results from subjecting a panel of substituted 1,1,1-trichloroalkanes¹² to CrCl₂ reduction are summarized in Table 1 and illustrate the generality of the method. As determined by ¹H NMR analysis, stereochemically

























pure (*Z*)- α -chlorostyrene (**2**) was smoothly generated from (2,2,2-trichloroethyl)benzene (**1**) in excellent yield (entry 1). Likewise, furan **3**¹³ and thiophene **5** gave good yields of the corresponding heterocyclic (*Z*)-olefins **4** and **6**, respectively. Notably, reduction of unactivated trichloride **7** to **8** (entry 4) and its homoallylic homolog **9** to *E,Z*-diene **10** (entry 5) proceeded with complete stereochemical integrity. The compatibility of the general procedure with a variety of common functionality was demonstrated by the conversion of aryl bromide **11**, acetone **13**, and bis-acetate **15** to **12** (entry 6), **14** (entry 7), and **16** (entry 8), respectively. Access to α -chloroenol ethers was achieved with outstanding results. Benzyl ether **17**, phenacyl **19**, α,β -unsaturated ester **21**, and allylic ether **23** provided the (*Z*)-1-chloro-2-alkoxy-1-alkenes **18** (entry 9), **20** (entry 10), **22** (entry 11), and **24** (entry 12) without incident.

Recent mechanistic studies¹⁴ provide important insights into the remarkable stereospecificity observed above. The 1,1,1-trichloroalkanes are initially transformed by CrCl₂ to a labile 1-chloro-1,1-dichromium carbenoid **25** (Scheme 1). Formally, the oxidative addition of Cr(II) into a C–Cl bond involves two consecutive single-electron transfers,¹⁵ thus accounting for the four equivalents of CrCl₂ needed for the generation of **25** (see General procedure). As a consequence of the high steric presentation by the *gem*-chromiums, **25** adopts a conformation that minimizes the interaction between the R group and the two chromiums. From this eclipsed conformation, *syn*- β -elimination of chromium hydride gives rise to (*E*)-chromium vinylidene carbenoid **26** exclusively and whence to (*Z*)-1-chloro-1-alkene upon quenching.

Keywords: alkenyl halides; carbenoids; chromium; enol ethers.


* Corresponding authors. E-mail: mioskow@aspirine.u-strasbg.fr; j.falck@utsouthwestern.edu

Table 1. Synthesis of (Z)-1-chloro-1-alkenes and (Z)-1-chloro-2-alkoxy-1-alkenes

| Entry | Reactant | Product | Yield (%) |
|-------|---|---|-----------|
| 1 |  |  | 93 |
| 2 |  |  | 91 |
| 3 |  |  | 89 |
| 4 |  |  | 98 |
| 5 |  |  | 95 |
| 6 |  |  | 83 |
| 7 |  |  | 97 |
| 8 |  |  | 93 |
| 9 |  |  | 92 |
| 10 |  |  | 95 |
| 11 |  |  | 92 |
| 12 |  |  | 97 |

^aRef. 12a. ^bRef.12b. ^cRef. 12c. ^dRef. 12d. ^eRef. 12e. ^fRef. 12f.

General procedure: 1,1,1-Trichloroalkane (0.4 mmol) in THF (2 mL) was added to a stirring, rt suspension of anhydrous CrCl_2^{16} (1.6 mmol, 4 equiv.) in THF (8 mL) under argon. After 10–12 h, the reddish reaction mixture was quenched with water and extracted with ether (3×8 mL). The combined ethereal extracts were evaporated in vacuo and the residue was purified by SiO_2 chromatography to give stereochemically pure (>98% by ^1H NMR) (Z)-1-chloro-1-alkene in the indicated yields (Table 1).

**Scheme 1.**

Acknowledgements

Financial support provided by the Robert A. Welch Foundation, NIH (GM31278, DK38226), CNRS, Instituts de Recherches Pierre Fabre (to R.B.), and an unrestricted grant from Taisho Pharmaceutical Co., Ltd. Dr. E. R. Fogel is warmly thanked for insightful discussions.

References

- (a) Jones, G. B.; Wright, J. M.; Plourde, G. W., II; Hynd, G.; Huber, R. S.; Mathews, J. E. *J. Am. Chem. Soc.* **2000**, *122*, 1937–1944; (b) Alami, M.; Gueugnot, S.; Domingues, E.; Linstumelle, G. *Tetrahedron* **1995**, *51*, 1209–1220.
- Guo, J.; Duffy, K. J.; Stevens, K. L.; Dalko, P. I.; Roth, R. M.; Hayward, M. M.; Kishi, Y. *Angew. Chem., Int. Ed.* **1998**, *37*, 187–192.
- Review of halogenated natural products: Gribble, G. W. *Prog. Chem. Org. Nat. Prod.* **1996**, *68*, 1–423.
- Gosney, I.; Lloyd, S. In *Comprehensive Organic Functional Group Transformations*; Katritzky, A. R.; Meth-Cohn, O.; Rees, C. W., Eds.; Pergamon Press: New York, 1995; Vol. 1, p. 719.
- Uenishi, J.; Kawahama, R.; Yonemitsu, O.; Tsuji, J. *J. Org. Chem.* **1998**, *63*, 8965–8975.
- Brown, H. C.; Blue, C. D.; Nelson, D. J.; Bhat, N. G. *J. Org. Chem.* **1989**, *54*, 6064–6067.
- (a) Takai, K.; Kataoka, Y.; Utimoto, K. *Tetrahedron Lett.* **1989**, *30*, 4389–4392; (b) Ratovelomanana, V.; Linstumelle, G. *Tetrahedron Lett.* **1981**, *22*, 315–318.
- Concellón, J. M.; Bernad, P. L.; Pérez-Andrés, J. A. *Angew. Chem., Int. Ed.* **1999**, *38*, 2384–2386.
- Pirrung, M. C.; Hwu, J. R. *Tetrahedron Lett.* **1983**, *24*, 565–568.
- Cleavage of benzyl ethers: Falck, J. R.; Barma, D. K.; Baati, R.; Mioskowski, C. *Angew. Chem., Int. Ed.* **2001**, *40*, 1281–1283. THF ethers: Baati, R.; Valleix, A.; Mioskowski, C.; Barma, D. K.; Falck, J. R. *Org. Lett.* **2000**, *2*, 485–487. Synthesis of 2-chloropropenyl and propargyl alcohols: Falck, J. R.; Barma, D. K.; Mioskowski, C.; Schlama, T. *Tetrahedron Lett.* **1999**, *40*, 2091–2094.
- For the Cr reduction of trichloromethyl carbinols, see: Wolf, R.; Steckhan, E. *J. Chem. Soc., Perkin Trans. 1* **1986**, 733–739.
- (a) Prepared (86–96% yield) from commercial bromide (1 mmol), CHCl_3 (2 mmol), and NaH (2 mmol) in DMF (15 mL) at 0°C for 6 h. See, Rachid Baati, Ph.D. Thesis, Université Louis Pasteur de Strasbourg, 2000; (b) from **9** (95%) via Pd/C/H₂ in EtOH; (c) from **9** via α -AD-mix (CH_2Cl_2 , 4°C; 89%), then $\text{Me}_2\text{C}(\text{OMe})_2/\text{PTSA}$ (CH_2Cl_2 , 23°C; 95%); (d) from **9** via α -AD-mix (CH_2Cl_2 , 4°C; 89%), then $\text{Ac}_2\text{O}/\text{py}$ (CH_2Cl_2 , 23°C; 92%); (e) according to Morimoto, T.; Sekiya, M. *Synthesis* **1981**, 308–310 using trichloroethanol and benzyl bromide (85%) or 2-bromo-4'-methoxybenzophenone (82%); (f) from **19** via olefination with $\text{Ph}_3\text{PCHCO}_2\text{Me}$ (C_6H_6 , 100°C; 85%) or $\text{Ph}_3\text{PCH}_2\text{Br}$ (BuLi, –78°C to rt, THF; 80%).
- Spectral data for **3**: ¹H NMR (CDCl_3 , 300 MHz) δ 4.01 (s, 2H), 6.39–6.42 (m, 1H), 6.45–6.48 (m, 1H), 7.43–7.46 (m, 1H); ¹³C NMR (CDCl_3 , 75 MHz) δ 53.21, 97.35, 110.90, 111.37, 143.13, 147.87. **9**: ¹H NMR (CDCl_3 , 300 MHz) δ 4.22 (s, 2H), 7.40–7.60 (m, 2H), 7.80–7.86 (m, 2H); ¹³C NMR (CDCl_3 , 75 MHz) δ 57.97, 98.71, 16.98, 127.37, 130.20, 133.24, 133.65. **10**: ¹H NMR (CDCl_3 , 300 MHz) δ 6.41 (d, 1H, $J=6.0$ Hz), 6.86 (d, 1H, $J=6.0$ Hz), 7.14–7.22 (m, 1H), 7.30–7.36 (m, 1H), 7.56–7.66 (m, 1H), 7.83 (d, 1H, $J=5.7$ Hz); ¹³C NMR (CDCl_3 , 75 MHz) δ 120.09, 124.17, 127.16, 129.14, 129.71, 130.91, 132.87, 134.12. **12**: ¹H NMR (CDCl_3 , 300 MHz) δ 2.50–2.60 (m, 2H), 2.73 (t, 2H, $J=7.2$ Hz), 5.77 (dd, 1H, $J=7.2$, 14.1 Hz), 6.04 (d, 1H, $J=6.9$ Hz), 7.20–7.38 (m, 5H); ¹³C NMR (CDCl_3 , 75 MHz) δ 28.87, 34.66, 117.37, 118.85, 126.26, 128.63, 130.95, 141.45. **15**: ¹H NMR (CDCl_3 , 300 MHz) δ 2.02 (s, 3H), 2.12 (s, 3H), 2.89 (dd, 1H, $J=1.80$, 15.30 Hz), 2.99 (dd, 1H, $J=7.5$, 15.3 Hz), 5.78–5.90 (m, 2H), 7.30–7.42 (m, 5H); ¹³C NMR (CDCl_3 , 75 MHz) δ 21.09, 21.12, 54.71, 71.03, 75.74, 96.66, 127.44, 128.90, 129.18, 135.66, 169.46, 169.74. **16**: ¹H NMR (CDCl_3 , 300 MHz) δ 2.03 (s, 3H), 2.10 (s, 3H), 5.60–5.70 (m, 1H), 5.94 (d, 1H, $J=9.0$ Hz), 6.06–6.17 (m, 2H), 7.20–7.40 (m, 5H). **19**: ¹H NMR (CDCl_3 , 300 MHz) δ 3.88 (s, 3H), 4.30 (s, 2H), 5.08 (s, 2H), 6.96 (d, 2H, $J=9.0$ Hz), 7.92 (d, 2H, $J=9.0$ Hz). **20**: ¹H NMR (CDCl_3 , 300 MHz) δ 3.88 (s, 3H), 5.08 (s, 2H), 5.24 (d, 1H, $J=4.2$ Hz), 6.38 (d, 1H, $J=4.2$ Hz), 6.96 (d, 2H, $J=9.0$ Hz), 7.92 (d, 2H, $J=9.0$ Hz).
- Baati, R.; Barma, D. K.; Falck, J. R.; Mioskowski, C. *J. Am. Chem. Soc.* **2001**, *123*, 9196–9197.
- Kochi, J. K.; Singleton, D. M. *J. Am. Chem. Soc.* **1968**, *90*, 1582–1589.
- Alternatively, CrCl_2 can be prepared from less expensive CrCl_3 via reduction with In powder (THF, 65°C, 10 h).